Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The combination of ifosfamide and paclitaxel (TI or TIP when combined with cisplatin/carboplatin) is a chemotherapy regimen used in various cancer treatments. Based on the search results, I'll provide comprehensive information about this drug combination. ## Description Ifosfamide + paclitaxel is a chemotherapy combination regimen used in the treatment of various cancers. This combination leverages the complementary mechanisms of action of both drugs to enhance anti-tumor activity. Paclitaxel is a taxane that stabilizes microtubules, preventing cell division, while ifosfamide is an alkylating agent that damages DNA, preventing cancer cell replication. The combination has shown significant activity in several cancer types, including testicular cancer, cervical cancer, head and neck squamous cell carcinoma (HNSCC), and uterine malignant mixed Mullerian tumors (MMMTs). When combined with platinum agents like cisplatin or carboplatin, the regimen is often referred to as TIP (paclitaxel-ifosfamide-cisplatin) or TICb (paclitaxel-ifosfamide-carboplatin)[1][3]. Preclinical data suggests that paclitaxel enhances the cell-killing effects of chemically induced DNA damage by alkylating agents like ifosfamide, particularly when paclitaxel is administered before ifosfamide. This sequence-dependent synergism is believed to occur through paclitaxel's inhibition of repair of DNA damage induced by ifosfamide[1]. ## Administration The combination is typically administered intravenously, with specific dosing schedules varying by cancer type and protocol: - Paclitaxel is usually given on day 1 at doses ranging from 175 mg/m² - Ifosfamide is typically administered over 1-3 days at doses ranging from 1000-4500 mg/m² total - When combined with platinum agents, cisplatin is often given at 40-80 mg/m² divided over 1-2 days[1][4] The regimen is generally repeated every 3-4 weeks, depending on the specific protocol and patient tolerance[4][6]. ## Efficacy The ifosfamide + paclitaxel combination has demonstrated efficacy in several cancer types: - In recurrent/metastatic head and neck cancer after platinum failure, the combination showed partial responses and disease stabilization in multiple patients[7] - When combined with cisplatin (TIP), it has shown high response rates in advanced cervical cancer[1] - In testicular cancer, TIP is used for disease that has spread or recurred[2] - For uterine and adnexal malignant mixed Mullerian tumors, the TICb combination (with carboplatin) has shown promising activity[3] ## Side Effects Common adverse effects include: - Severe neutropenia (grade 4 in up to 87% of patients in some studies) - Febrile neutropenia - Thrombocytopenia and anemia - Neuropathy - Ifosfamide-induced encephalopathy (reported in 10-30% of patients receiving high-dose ifosfamide) - Hemorrhagic cystitis[4][6] Prophylactic G-CSF support is often recommended to manage neutropenia[1][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ifosfamide + paclitaxel.